Ying Jie Chee

Ying Jie Chee


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
YCYing Jie Chee
Ying Jie Chee
SNShereen Jia Huey Ng
Shereen Jia Huey Ng
EYEster Yeoh
Ester Yeoh

18 November 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
YCYing Jie Chee
Ying Jie Chee
BFBingwen Eugene Fan
Bingwen Eugene Fan
BYBarnaby Edward Young
Barnaby Edward Young
RDRinkoo Dalan
Rinkoo Dalan
DLDavid C. Lye
David C. Lye

18 June 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
YCYing Jie Chee
Ying Jie Chee
STSeng Kiong Tan
Seng Kiong Tan
EYEster Yeoh
Ester Yeoh
Coronavirus disease 2019 (COVID‐19) is a global pandemic that is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus‐2. Data from several countries have shown higher morbidity and mortality among individuals with chronic metabolic diseases, such as diabetes mellitus. In this review, we explore the contributing factors for poorer prognosis in these individuals. As a significant proportion of patients with COVID‐19 also have diabetes mellitus, this adds another layer of complexity to their management. We explore potential interactions between antidiabetic medications and renin–angiotensin–aldosterone system inhibitors with COVID‐19. Suggested recommendations for the use of antidiabetic medications for COVID‐19 patients with diabetes mellitus are provided. We also review pertinent clinical considerations in the management of diabetic ketoacidosis in COVID‐19 patients. In addition, we aim to increase clinicians’ awareness of the metabolic effects of promising drug therapies for COVID‐19. Finally, we highlight the importance of timely vaccinations for patients with diabetes mellitus.

Verified
Journal Article
Open access
PDF file
YCYing Jie Chee
Ying Jie Chee
RDRinkoo Dalan
Rinkoo Dalan
CCChristine Cheung
Christine Cheung
The endothelium is pivotal in multiple physiological processes, such as maintaining vascular homeostasis, metabolism, platelet function, and oxidative stress. Emerging evidence in the past decade highlighted the immunomodulatory function of endothelium, serving as a link between innate, adaptive immunity and inflammation. This review examines the regulation of the immune–inflammatory axis by the endothelium, discusses physiological immune functions, and explores pathophysiological processes leading to endothelial dysfunction in various metabolic disturbances, including hyperglycemia, obesity, hypertension, and dyslipidaemia. The final section focuses on the novel, repurposed, and emerging therapeutic targets that address the immune–inflammatory axis in endothelial dysfunction.

21 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
YCYing Jie Chee
Ying Jie Chee
RDRinkoo Dalan
Rinkoo Dalan
Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to rise. A substantial increase in the burden of CVD and renal disease, alongside the socioeconomic implications, would be anticipated. Adopting a purely glucose-centric approach focusing only on glycemic targets is no longer adequate to mitigate the cardiovascular risks in T2DM. In the past decade, significant advancement has been achieved in expanding the pharmaceutical options for T2DM, with novel agents such as the sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide receptor agonists (GLP-1 RAs) demonstrating robust evidence in cardiorenal protection. Combinatorial approaches comprising multiple pharmacotherapies combined in a single agent are an emerging and promising way to not only enhance patient adherence and improve glycemic control but also to achieve the potential synergistic effects for greater cardiorenal protection. In this review, we provide an update on the novel antidiabetic agents in the past decade, with an appraisal of the mechanisms contributing to cardiorenal protection. Additionally, we offer a glimpse into the landscape of T2DM management in the near future by providing a comprehensive summary of upcoming agents in early-phase trials.

15 April 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
YCYing Jie Chee
Ying Jie Chee
YCYing Jie Chee
Ying Jie Chee
RARebecca Tian Mei Au
Rebecca Tian Mei Au
YKYin Chian Kon
Yin Chian Kon
There is a paradigm shift in the detection of phaeochromocytomas with more being identified as adrenal ‘incidentalomas’. While majority of these individuals are asymptomatic, they are nevertheless at risk of subtle cardiovascular dysfunction and phaeochromocytoma crises. Therefore, early resection of phaeochromocytomas, even if subclinical, is recommended. However, the perioperative management can be challenging as the normotension can limit the initiation and titration of alpha-blockade. We present a man in his 60s with a subclinical phaeochromocytoma, discuss the evaluation of an incidentally discovered adrenal nodule, as well as the practical considerations in the perioperative management.